Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

New England Journal of Medicine - United States
doi 10.1056/nejmoa050516
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Massachusetts Medical Society

Related search

Red Cell Abnormalities Associated With Sulphasalazine Maintenance Therapy for Ulcerative Colitis.

Gut
Gastroenterology
1975English

Cost-Utility Analysis of Infliximab and Adalimumab for Refractory Ulcerative Colitis

Cost Effectiveness and Resource Allocation
Health Policy
2009English

A Type II Segmental Vitiligo Developed Under Infliximab Treatment for Ulcerative Colitis

Annals of Dermatology
Dermatology
2017English

Letter: Dose Optimising Infliximab in Acute Severe Ulcerative Colitis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Letter: Should We Intensify Infliximab in Acute Severe Ulcerative Colitis?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Ileostomy for Ulcerative Colitis

BMJ
1942English

Treatment for Ulcerative Colitis

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
2010English

Long-Term Efficacy of Infliximab for Refractory Ulcerative Colitis: Results From a Single Center Experience

BMC Gastroenterology
MedicineGastroenterology
2014English

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy